[8-K] EXOZYMES INC. Reports Material Event

Rhea-AI Filing Summary

eXoZymes Inc. filed an 8-K announcing an updated Investor Presentation as of November 13, 2025. The update, tied to its NCTx business, is furnished under Item 8.01 (Other Events) and provided as Exhibit 99.1.

The company’s common stock trades on the Nasdaq Capital Market under the symbol EXOZ. The report lists the company’s principal office at 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016.

false 0002010788 0002010788 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 13, 2025

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

Nevada		001-42204		83-4550057
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (626) 415-1488

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		EXOZ		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 — Other Events.

Attached is an updated Investor Presentation of eXoZymes Inc., a Nevada corporation, as of November 13, 2025, in connection with its NCTx business.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits		Description of Exhibit
99.1		Investor Presentation of eXoZymes Inc. for NCTx as of November 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13, 2025	EXOZYMES INC.
	By	/s/ Fouad Nawaz
		Fouad Nawaz,
		Vice President, Finance

FAQ

What did eXoZymes (EXOZ) announce in this 8-K?

The company furnished an updated Investor Presentation as of November 13, 2025, related to its NCTx business under Item 8.01 (Other Events).

What is included in Exhibit 99.1 for eXoZymes (EXOZ)?

Exhibit 99.1 is the updated Investor Presentation of eXoZymes Inc. for NCTx, dated November 13, 2025.

Which business area does the presentation cover for EXOZ?

The presentation is connected to eXoZymes’ NCTx business.

Where is eXoZymes headquartered?

750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016.

What exchange lists eXoZymes common stock and under what ticker?

Nasdaq Capital Market under the ticker EXOZ.

Who signed the report for eXoZymes?

Fouad Nawaz, Vice President, Finance, signed the report.